Episódios
-
Our guest today is Dr. Anurag Singh, the chief medical officer at Timeline Nutrition, a Swiss life-science company that focuses on ways to improve mitochondrial and cellular health. Anurag is particularly known for his research into the gut metabolite, urolithin-A, which has been shown to improve muscle strength, protect immune systems and optimize mitochondrial efficiency.
Anurag is an MD in internal medicine with a Ph.D. in immunology. He has led more than 50 randomized clinical trials, many of them focusing on urolithin-A over the past decade.
In today’s episode we talk to Anurag about his investigations into urolithin-A and the role it plays as a postbiotic that enhances mitochondrial function. Foods that contain the polyphenols needed to produce urolithin-A include pomegranates, strawberries, raspberries and walnuts.
Show notes:
[00:02:48] Marcas starts the interview by mentioning that Anurag grew up in India, in Lucknow, and asks what Anurag’s childhood was like.
[00:03:56] Marcas follows up, asking Anurag what he was like as a kid, given the competitive environment he grew up in.
[00:04:47] Ken asks Anurag if it is true that, at an early age, his parents noticed he was gifted in biology and encouraged him to think about pursuing medical school.
[00:05:47] Ken asks if Anurag started medical school at only 18 years of age.
[00:06:28] Marcas explains that Anurag went to India’s Armed Forces Medical College for training in internal medicine and asks if it is true that this is one of India’s top medical schools.
[00:07:07] Marcas explains that it is typical for graduates from the India Armed Forces Medical College to serve a few years in the Indian army after graduation. Marcas asks Anurag to tell the story of how he was able to go to the U.S. post-graduation rather than serving time in the army.
[00:08:00] Ken asks if Anurag’s interest in medical research led him to pursue a Ph.D. in immunology.
[00:08:56] Ken asks Anurag what his Ph.D. research was on.
[00:09:37] Marcas mentions that in 2009, Anurag accepted a position at Nestlé at a time when the company was entering into the space between food and pharma. Marcas asks Anurag how this move came about.
[00:11:20] Ken explains that Anurag quickly became medical director at Nestlé and started initiating clinical trials around food and allergies, as well as research on aging and how the immune system declines with age. Ken asks Anurag to explain what his time at Nestle was like.
[00:12:53] Marcas mentions how the shift from practicing physician to research scientist is an interesting course and asks Anurag to talk about a mentor who gave him the advice that led to his career shift.
[00:13:55] Ken mentions that in 2014 Anurag joined a Swiss company, Amazentis, as chief medical officer, and later became the lead for their medical and clinical research strategies. Ken asks Anurag to talk about the company and the work he does.
[00:15:00] Ken asks Anurag to describe the relationship between Amazentis and Timeline.
[00:15:42] Marcas asks Anurag to elaborate on his biotech approach to nutrition science, and how hard biology is used in his nutritional approaches at Amazentis.
[00:18:02] Marcas asks Anurag to give listeners an overview of the function and importance of mitochondria.
[00:19:15] Ken asks Anurag if there are any other benefits to good mitochondrial health, other than an increased energy supply.
[00:20:24] Ken asks Anurag to define the terms “mitochondrial biogenesis” and “mitophagy.”
[00:22:13] Marcas pivots to discuss age-related frailty and healthspan, specifically bringing up a study Anurag conducted on a Dutch population comparing active seniors to sedentary seniors.
[00:25:09] Ken mentions that Marcas likes to refer to exercise as medicine, given its potent effects on a wide variety of biomarkers. Ken asks Anurag to discuss the importance of exercise.
[00:26:59] Following up on the Dutch study, -
Few people know as much about inflammation and neuroscience as Dr. Kevin Tracey does.
In this episode of STEM-Talk, we learn much from Tracey, who was the first to identify the inflammatory reflex, a physiological mechanism that regulates the body’s immune response to injury and invasion.
He is a neurosurgeon, a pioneer in bioelectrical medicine and president and CEO of the Feinstein Institutes for Medical Research in Manhasset, N.Y. The conversation in this episode covers a career spent working on “producing tomorrow’s cures today” in the treatment of inflammatory diseases, including:
How the death of his mother from a brain tumor when Tracey was 5 years old ultimately influenced his scientific journey.
How the death of a young patient of his from sepsis further fueled his path, leading him to the insight that “good science begins with hard questions,” as Tracey shared in a TedTalk.
The molecular mechanisms of inflammation and the use of vagus nerve stimulation to treat it.
His 1987 discovery of tumor necrosis factor (TNF), which contributed to a new class of drugs for inflammatory and autoimmune diseases.
Another discovery that allowed him and his colleagues to merge neuroscience and immunology.
His work on “The Inflammatory Reflex”, which emphasized the basic neural pathway that reflexively monitors and adjusts the inflammatory response.
A sketch he drew while having lunch, which laid out how treating inflammatory diseases using a bioelectronic device might be possible.
What advances in bioelectronic medicine he envisions in the next decade, and much more.
[00:03:04] Dawn asks Kevin to tell the story of how he developed an interest in science that evolved into him becoming a neurosurgeon.
[00:04:56] Dawn mentions that Kevin was a curious youth and asks if it is true that after getting his first car, Kevin removed the entire engine because he wanted to better understand how to do a valve job.
[00:06:33] Ken mentions that after Kevin graduated from high school, he enrolled in Boston College where he earned a bachelor’s degree in chemistry. Ken explains that Kevin went to Boston University Medical School for his M.D. and asks Kevin about the transition.
[00:08:41] Ken asks if it is true that during Kevin’s first year at medical school his classmates had better luck finding him on the golf course than in the classroom.
[00:10:42] Dawn asks Kevin about his transition from medical school to the neurological surgery training program at New York Hospital, home of the Cornell University Medical College.
[00:13:11] Dawn pivots to talk about sepsis, which kills more than 350,000 people annually. She asks Kevin to discuss his tragic story of treating a patient with sepsis as a young neurosurgeon and how that changed the trajectory of his career.
[00:16:38] Ken explains that since the aforementioned incident, Kevin has focused on determining why septic shock occurs. Ken refers to a Ted Talk of Kevin’s in which he says, “good science begins with hard questions.” Ken asks Kevin to elaborate on this point.
[00:20:49] Dawn mentions that Kevin often describes himself as a brain surgeon who is fascinated by inflammation. Dawn asks Kevin how he responds when people ask him what inflammation is.
[00:22:29] Ken follows up by explaining that in 1987 Kevin made progress investigating inflammation with his discovery of tumor necrosis factor (TNF), which contributed to a new class of drugs for inflammatory and autoimmune diseases. Ken asks Kevin to discuss this discovery.
[00:25:56] Dawn mentions that in the late ‘90s, Kevin made another discovery that allowed him and his colleagues to merge neuroscience and immunology. Before getting into that discovery, Dawn asks Kevin to explain how humans have simple reflex circuits that harmonize the activity of our organs. She also asks him to talk about Charles Sherrington’s Nobel Prize-winning research, which laid the groundwork for contemporary neuroscience by... -
Estão a faltar episódios?
-
In today’s Ask Me Anything episode, Ken and Dawn answer a wide range of questions that cover:
A recent FDA approval of a neural implant device for people with degenerative neuromuscular disease or spinal-cord injuries.
Global security in the age of AI.
A study that looked at ways to optimize glymphatic clearance for people with acute or chronic sleep deprivation.
Why more gyms don’t offer blood-flow restriction classes for their clients.
Developments in the realm of Generative AI.
The tradeoffs between a low-carb diet versus a ketogenic diet.
A study on Alzheimer’s titled, “APOE 4 Homozygosity Represents a Distinct Genetic Form of Alzheimer’s Disease.”
Plus, Ken reveals his favorite science-fiction author.
[00:02:38] Dawn opens the episode with a question for Ken about the FDA’s recent approval of a neural implant device which is touted as a means of allowing people with degenerative neuromuscular disease, or spinal-cord injuries, to interface with external technology via neural signals. The listener asks Ken for his insights into what is being called “brain-computer interface technologies.”
[00:05:44] A listener asks Ken if he has a favorite science-fiction writer, or if there is a particular sci-fi series/story that really moves him.
[00:08:48] Multiple listeners ask Ken about a paper recently published titled: “APOE 4 Homozygosity Represents a Distinct Genetic Form of Alzheimer’s Disease.” Listeners ask if it is true that people with two copies of APOE4 allele are certain to develop the disease.
[00:19:30] A listener asks Ken about his time on the National Security Commission on Artificial Intelligence. The commission issued its report five years ago with specific recommendations on how the government should prepare for and defend against the national security implications of AI. Ken shares his thoughts on the implementation of the commission’s recommendations.
[00:21:16] A listener asks Dawn about her collaboration with Dr. Jeff Iliff that looked at a potential approach to optimizing glymphatic clearance for people with acute or chronic sleep deprivation.
[00:27:10] A listener asks Ken why more gyms and physical therapy centers don’t have blood flow restriction devices (BFR) available for their clientele, given that studies have shown that BFR improves strength and muscle mass in both young and older adults. (Two STEM-Talk episodes that cover blood-flow restriction include episode 34 and episode 161.
[00:28:38] A listener asks Ken for his thoughts on AI given the recent developments in the field, particularly in the realm of Generative AI, with programs like Chat GPT becoming a household name. The listener mentions that one of their friends thinks that AI is about to peak, and another says that AI is just getting warmed up.
[00:37:00] A listener writes that they are astounded at how many disorders can be treated with a ketogenic diet and mentions that they themselves have difficulty with a ketogenic diet. Instead, the listener eats low-carb diet and asks if the benefits of a low-carb, non-ketogenic diet are similar to a ketogenic one.
[00:38:19] A listener asks if Ken could talk about carotid scans and if this is a test that those with high LDL should consider getting.
[00:40:17] A 72-year-old listener explains how they structure their daily exercise routine between resistance and endurance training. The listener asks Ken whether they should focus more on resistance training as they are beginning to lose strength, and if so, how they should implement that given their age and the increasing risk for injury.
[00:45:51] To wrap up this episode, a listener asks Ken if he has any new annoyance that he would like to share, as he did in 2022, when he noted his disdain for the phrase “new normal” and the prevalence of cellphone addiction.
Links:
Learn more about IHMC
STEM-Talk homepage
Ken Ford bio
Ken Ford Wikipedia page
Dawn Kernagis bio -
Today Dr. David LeMay steps in to co-host with Dr. Ken Ford for our interview with Dr. Charles Serhan. Charles is a Harvard professor best known for his discovery of specialized pro-resolving mediators. SPMs are molecules that can activate the natural resolution of inflammation and help people avoid anti-inflammatory drugs. The discovery of SPMs spurred a paradigm shift in our understanding of inflammation and human disease.
Charles is the Simon Gelman Professor of Anesthesia at Harvard Medical School and the director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital. He also is a co-director of the Brigham Research Institute.
David, who was our guest on Episode 69 of STEM-Talk, is a sports medicine and rehabilitation physician with a Pensacola, Florida practice that focuses on lifestyle and performance medicine. He also is a visiting research scientist here at IHMC.
Show notes
[00:03:33] David opens the interview mentioning that Charles grew up in New York City with a passion for music. David explains that Charles learned to play the vibraphone in junior high and played professionally for a year before going to college. David asks Charles why he decided to pursue science instead of music.
[00:04:22] Ken asks Charles what kind of vibraphone he plays.
[00:06:02] Ken asks, aside from the desire to help people, if there was something particular about studying science that Charles really enjoyed.
[00:06:45] David asks about Charles’ experience at the State University of New York at Stonybrook studying biochemistry and immunohistochemistry.
[00:07:16] David asks if there was any carry over of skills for Charles from his career in music to his career in science.
[00:08:16] Ken mentions that after Charles earned his bachelor's degree, one of his professors persuaded him to go to New York University for a master's and Ph.D. Ken also mentions that at the time Charles worked in the lab of Gerald Wiseman at Woods Hole Marine Biological Laboratory and asks about that experience.
[00:12:37] David asks if this experience led Charles to a focus on neutrophil membrane remodeling for his Ph.D.
[00:13:59] David asks Charles if it was at the Karolinska Institute where he met his future wife.
[00:14:38] Ken asks Charles about one of his mentors, Michael Heidelberg, who gave Charles advice about how to be a good scientist.
[00:17:13] David explains that in the 1990's Charles discovered Specialized Pro-Resolution Mediators and has since pioneered a new field on the utility of SPMs for a variety of inflammatory diseases.
[00:25:01] Ken backs up to ask Charles what drew him to study inflammation in the first place and how that led him to do more research on the subject than any other scientist.
[00:26:26] David asks Charles to touch on some different types of inflammation that the body experiences.
[00:35:12] Ken asks Charles about how a trip to Asia during which he developed a hole in his intestines, resulted in first-hand experience on the importance of controlling inflammation.
[00:41:00] David asks if Charles was taking any non-steroidal anti-inflammatory medications when he developed peritonitis.
[00:41:53] David asks Charles to explain what non-steroidal anti-inflammatory medications do to the healing process.
[00:45:35] David brings up a recent discovery in animal models that as animals age, their ability to produce resolution mediators declines, possibly contributing to the loss of muscle mass with age.
[00:48:09] Ken asks Charles to talk about the explosion of research into the potential therapeutic applications of SPMs in the treatment of a variety of chronic diseases known to be driven in part by chronic inflammation.
[00:51:06] David asks Charles to explain the differences between resolvins, protectins, and maresins, as well as what role each plays in the healing process.
[00:56:04] Ken mentions a review article that Charl... -
Dave Feldman is the founder of the Citizen Science Foundation and is known for his research into the ketogenic diet. Dave is a software engineer by training who embraced a ketogenic diet to avoid his progression toward type 2 diabetes. he joins us on this episode of STEM-Talk to share that journey.
After undertaking the high-fat/low-carbohydrate diet, Dave’ LDL cholesterol spiked. Dave used his training as an engineer to start learning everything he could about cholesterol and lipids. What he learned led him to create the website Cholesterol Code, a research hub for information and emerging data on cholesterol, particularly in the context of a low-carbohydrate lifestyle.
Dave’s Citizen Science Foundation is designed to support projects and research that promote collaborative efforts across multiple disciplines, both in and outside formal scientific institutions.
Show notes:
[00:02:53] Dawn opens the interview asking Dave what he was like as a kid.
[00:03:44] Dawn mentions that Dave divided his time as a child between Denver and Wichita due to his parents’ divorce and asks Dave what the best part of his childhood was.
[00:04:28] Ken mentions that Dave has described both his parents as graphic artists and Bohemian, “hippie spirit” types. Ken asks what he learned from them that fueled his interests and goals.
[00:05:46] Ken asks about Dave’s first computer, which was a Commodore 64, as well as his early experience with computers.
[00:08:50] Dawn mentions that Dave’s interest in computers came in a time before the internet and asks what he learned about computing in those days.
[00:10:51] Dawn explains that since Dave grew up in the 1980s, there was not much in the way of computer science curriculum in schools and asks Dave how he supported his interest in programming.
[00:12:33] Ken asks Dave about how self-directed learning has been a theme throughout his whole life.
[00:14:35] Dawn asks Dave about his childhood hobbies, including running and competitive storytelling.
[00:17:01] Ken asks how Dave’s experiences in forensic debate in high school helped his career later in life.
[00:18:56] Dawn mentions that Dave initially attended film school and asks if it is true that Dave’s side hustle of doing contract software work overtook his original plan to graduate.
[00:20:49] Dawn asks about Dave’s experiences working in the game platform development business in Las Vegas, as well as what these experiences taught him.
[00:22:23] Ken asks Dave about a “the piece of paper” that Dave says changed his life in 2015.
[00:28:58] Ken follows up, asking Dave if he checked his LDL-P or his ApoB at the same time as his cholesterol levels.
[00:30:37] Ken mentions that he knows some people that when consuming a ketogenic diet did not see a substantial increase in LDL-C, but did experience a substantial elevation of LDL-P.
[00:35:03] Ken pivots to discuss a paper that Dave and others published in Current Developments in Nutrition in 2022 titled: “Elevated LDL Cholesterol with a Carbohydrate-Restricted Diet: Evidence for Lean Mass Hyper-Responder Phenotype.” Ken asks Dave to describe what it means to be a lean mass hyper-responder.
[00:40:19] Ken mentions his caution against the term lean mass hyper-responder, as it is unclear what “lean mass” refers to in this case. Ken goes on to say that while the lean mass hyper-responder phenotype can be objectively measured in terms of LDL, HDL and triglyceride levels, the lean mass aspect is often measured in these studies with BMI, which is unable to measure body composition. Ken asks Dave what his thoughts are on this and if he would like the possibility of moving away from BMI and towards DEXA scans.
[00:43:37] Ken mentions that Dave’s original article describing the lean mass hyper-responder phenotype has received a lot of response from individuals claiming to fall into that category. While it is difficult to get a precise estimate of the popul... -
Dr. Alessio Fasano, who is considered the world’s leading expert in celiac disease and gluten-related disorders, returns for his second appearance on STEM-Talk. Although just 2 million Americans have celiac disease, an estimated 20 million Americans suffer from gluten sensitivity.
Alessio is a professor and director of the Mucosal Immunology and Biology Research Center at Massachusetts General Hospital. In addition to celiac disease and gluten-related disorders, Alessio’s research is also focused on the microbiome, intestinal permeability and autoimmune disorders, which he discussed in his first interview on STEM-Talk, episode 20.
Since Alessio’s first appearance on STEM-Talk in 2016, he has published two books, “Gluten Freedom” and “Gut Feelings: The Microbiome and Our Health,” which we discuss in today’s interview. We also talk to Alessio about an exciting new project that’s bringing together an international consortium of researchers and scientists for a long-term study that will follow infants who are genetically at risk of developing celiac.
Alessio is a researcher and physician who wears many hats. He is the director of the Center for Celiac Research and Treatment and chief of the Division of Pediatric Gastroenterology and Nutrition at Mass General Hospital. He also is a professor of pediatrics at Harvard Medical School and a professor of nutrition at Harvard’s T.H. Chan School of Public Health.
Show notes:
[00:03:58] Marcas opens the interview welcoming Alessio back to STEM-Talk, mentioning that since his last appearance he has written two books: Gluten Freedom and Gut Feelings: The Microbiome and Our Health. Marcas asks Alessio how he became interested in pediatrics and gastroenterology.
[00:05:42] Ken mentions that Alessio moved to the U.S. in the 1990s and spent 20 years in Maryland at the Center for Vaccine Development in Baltimore. Ken goes on to mention that while Alessio was there, he founded The Center for Celiac Research in 1996, and in 2003, Alessio accepted an offer to join Massachusetts General Hospital. Ken asks how that move came about.
[00:08:53] Marcas asks about Alessio’s early career working on cholera, where he discovered the zonula occuldens toxin, the bacteria that causes cholera. Marcas asks Alessio to talk about this finding and the insights he gleaned from it.
[00:16:03] Ken asks about Alessio’s discovery of zonulin, which is the molecule that modulates gut permeability in humans. Ken asks Alessio to share how this discovery led him to investigate celiac disease, which is triggered by gluten.
[00:20:25] Ken asks Alessio what his thoughts are on why the medical community, historically, has not taken celiac disease seriously.
[00:24:08] Marcas mentions that as we age, there is evidence that the gut becomes leakier, which is highly related to chronic inflammation. Marcas asks Alessio whether this happens to the gut over time due to diet and lifestyle rather than the typical aging process.
[00:28:45] Ken mentions that there has been an increase in the diagnosis of celiac disease. Ken asks Alessio if that is due to an actual increase in the prevalence of the disease, or is it tied to a growing appreciation that clinicians have now for the disease?
[00:29:32] Marcas mentions that Alessio’s book, Gluten Freedom, which he co-authored with his colleague Susie Flaherty, was referred to by the Celiac Disease Foundation as “a must have,” and “an excellent reference for those with gluten related disorders.” Marcas asks Alessio about this reception to his book.
[00:31:24] Marcas mentions that the only viable treatment for individuals with celiac disease has been a gluten-free diet, with pharmaceutical companies having had little interest until recently in investigating the disease. Now there are more than 20 drug therapies in development for celiac. Marcas asks Alessio about the progress being made to develop pharmacological interventions for celiac. -
Today we have Dr. Nicholas Norwitz, 28, a third-year Harvard Medical School student whose research into the applications of a ketogenic diet as metabolic medicine has attracted a significant following.
For a number of years during his youth, Nick suffered from a number of debilitating diseases, including osteoporosis, ulcerative colitis, and inflammatory bowel disease. In today’s interview, we talk to Nick about research that led him to adopt a ketogenic diet that put him back on the road to metabolic health.
After graduating from Dartmouth College in 2018 with a degree in cellular and molecular biology, Nick attended Oxford University where he earned a Ph.D. in metabolism and nutrition. He is the author of peer-reviewed scientific papers and textbook chapters on topics including Alzheimer’s disease, cardiovascular disease, diabetes, gastrointestinal health, genetics osteology and Parkinson’s disease.
Show notes:
[00:02:53] Marcas opens the interview mentioning that Neck grew up in Boston, and asks if it’s true that he was a very curious kid growing up.
[00:04:09] Marcas asks Nick if as a young child he always knew he wanted to be a physician and a scientist.
[00:05:40] Ken mentions that Nick was a runner in high school, and as is the case with many runners, this led to fractures. However, Ken goes on to say that these fractures did not resolve for Nick, and asks what he learned as a result.
[00:11:08] Ken asks about Nick’s eating habits in college as he loved to cook and bake.
[00:15:40] Marcas follows up, asking Nick at what point during his Ph.D. training was he admitted to palliative care.
[00:21:01] Marcas pivots to talk about the need for incorporating metabolic health into our health-care system. He mentions that Nick once said that “we live in a society where our social norms and ecosystem, with respect to health and food, are extremely dysfunctional,” and asks Nick to elaborate on this.
[00:26:16] Ken mentions a paper that Nick recently published titled, “Oreo Cookie Treatment Lowers LDL Cholesterol More Than High Intensity Statin Therapy in a Lean Mass Hyper-Responder on the Ketogenic Diet: A Curious Crossover Study.” To provide some background, Ken mentions that some people on a ketogenic or low carb diet experience a dramatic increase in LDL cholesterol. The rationale behind Nick’s paper being that if it is the removal of carbohydrates that causes this increase in LDL, adding carbohydrates back into one’s diet should bring LDL levels back down. Ken asks Nick to talk about this experiment and how he designed it.
[00:35:44] Ken mentions that the paper seems to be designed to be provocative, as simply testing carbohydrates against statins would likely have not gotten as much attention as using Oreo cookies.
[00:37:00] Marcas mentions that in the Oreo cookie vs statin experiment, Nick’s original fasted-morning LDL was 384, before dropping it with Oreos, then doing a washout before dropping it again with statins. Marcas asks Nick what his fasted-morning LDL was post washout, prior to the statin intervention.
[00:39:07] Marcas brings up Nick’s paper titled: “The Lipid Energy Model: Reimagining Lipoprotein Function in the Context of Carbohydrate Restricted Diets.” Marcas goes on to mention that the aim of the paper was to propose a mechanistic explanation for the “lean mass hyper-responder phenotype.” Marcas asks Nick to give listeners an overview of the lipid-energy model.
[00:45:18] Ken mentions that according to Nick, BMI is not a requirement for classification as a lean mass hyper-responder. Nick’s paper, however, uses BMI data. Ken mentions that he finds BMI relatively useless and asks why Nick did not use DEXA scans instead.
[00:48:52] Ken mentions that adipose tissue contains roughly 25 percent of total body cholesterol, and we know that LDL binding to adipose cell membranes is competitively inhibited by HDL. Ken asks if lean mass hyper-responders were found to hav... -
Dr. Vyvyane Loh returns to STEM-Talk for her second appearance to talk about atherosclerotic heart disease. Also known as ASCVD, the disease has been reported to affect 26 million people in the U.S., and annually leads two million hospitalizations and more than 400,000 deaths.
Vyvyane is a board-certified physician in obesity and internal medicine. In episode 142 of STEM-Talk, we talked to Vyvyane about her Boston-based preventative-care practice that specializes in weight management and the treatment of chronic metabolic diseases such as diabetes, hypertension and dyslipidemia.
In today’s podcast, Vyvyane and host Dr. Ken Ford talk about ASCVD as well as recent research that has shown substantial individual variability in the response to statin therapy as a way to lower cardiovascular risk. Vyvyane and Ken also discuss how the current knowledge base informing clinical practice in medicine today is far behind advances in the biological sciences, especially in the field of ASCVD.
Show notes:
[00:03:15] Ken welcomes Vyvyane back to STEM-Talk and encourages listeners to check out Vyvyane’s first interview, episode 142. Ken goes on to mention that atherosclerotic heart disease has been reported to affect 26 million people in the U.S. and that despite the wide use of statins as a primary prevention of atherosclerotic heart disease, the effects of this treatment have been variable with regards to major adverse cardiac events. Ken asks Vyvyane for her thoughts.
[00:05:32] Ken asks Vyvyane about recent developments in atherosclerotic heart disease research, specifically in regard to the anatomical aspects of the disease-model itself.
[00:08:43] Ken follows up asking Vyvyane how the knowledge we have of glycocalyces, and the endothelial lining of the blood vessels, could affect clinical practice.
[00:12:19] Ken asks if there are any other recent updates to the anatomical model of atherosclerotic disease that people should be aware of.
[00:13:09] Ken asks Vyvyane how she would characterize the significance of the tunica intima of the coronary artery.
[00:15:25] Ken asks about the third recent anatomical highlight to blood vessels relevant to the discussion.
[00:19:19] Ken follows up, asking if this is how the vasa vasorum contributes to our understanding of the development of atherosclerosis.
[00:21:05] Ken asks Vyvyane to explain what endothelial dysfunction is and what are its downstream effects.
[00:26:09] Ken asks Vyvyane to expound on the link between atherosclerotic disease and auto-immunity.
[00:31:01] Ken asks, given the link to inflammation, if there have been any therapeutic developments made in the treatment of atherosclerotic disease.
[00:34:54] Ken asks about the vaccine that is being developed for atherosclerosis.
[00:37:53] Ken mentions that another recent development in the field is the growing appreciation for clonal hematopoiesis in atherosclerosis. Ken asks Vyvyane to explain what clonal hematopoiesis is.
[00:39:55] Ken asks Vyvyane what some actionable takeaways are from our discussion on atherosclerosis that listeners can take home with them.
[00:43:17] Ken asks Vyvyane about her passion for dance, and how much time she invests in that area of her life.
[00:48:11] Ken follows up asking Vyvyane what drives her to pursue dance so passionately.
[00:53:34] In closing the interview, Ken encourages listeners to check out Vyvyane’s podcast as well as her website.
Links:
Vyvyane Loh website
Vlmdrounds.com
Learn more about IHMC
STEM-Talk homepage
Ken Ford bio
Ken Ford Wikipedia page
-
Today we have Dr. Johnathan Edwards, an anesthesiologist and medical practitioner who specializes in human health and optimization. He is perhaps best known for treating mental health conditions with ketamine, a dissociative anesthetic that is used for general anesthesia, pain relief, depression and epilepsy. John also uses ketamine to help adolescents overcome depression and suicidal ideation.
In today’s interview, we talk about his new book, “The Revolutionary Ketamine: The Safe Drug That Effectively Treats Depression and Prevents Suicide.” More Americans have died from suicide than all the wars since Vietnam. The suicide rate among 10- to-24-year-olds in this country increased 62 percent from 2007 through 2021. As John points out in today’s discussion, most people are not aware that American children between the ages of 10 and 14 are twice as likely to die from suicide than homicide.
Show notes:
[00:02:39] Dawn explains that suicide is a pressing problem in America, with more Americans dying of suicide than from all the wars since Vietnam. She also points out that police and firefighters are more likely to die from suicide than in the line of duty. John then gives an overview of ketamine and its ability to help treat depression and suicidal thoughts.
[00:06:56] Dawn pivots to mention the dark side of ketamine, including ketamine misuse and overdose. Recent studies have reported a worldwide increase in ketamine misuse and overdoses. Back in October, Mathew Perry, one of the stars of the popular sit-com “Friends,” died from what the Los Angeles cororner described as the acute effects of ketamine. Because this was such a high-profile case, Dawn asks John to discuss the potential adverse effects of ketamine.
[00:13:03] Ken mentions a 2022 study in the American Journal of Drug and Alcohol Abuse that looked at ketamine overdoses and deaths. The study found no cases of overdose or death from ketamine used in a clinical setting as therapy for depression. Ken asks if there is anything John would like to add about ketamine and safety.
[00:13:059] Dawn shifts to talk about John’s background, mentioning that he grew up riding dirt bikes and eventually raced bikes professionally.
[00:15:18] Ken asks John to share his story of how a junior college professor sparked his interest in science.
[00:17:49] Dawn mentions that John jumped around from Eastern Virginia Medical School, to the University of Reno, to the University of Utah, at which point it looked as though he was heading for a career in internal medicine. Dawn asks why John changed his mind and decided not to pursue that career path.
[00:19:40] Dawn asks John what led him to the University of South Florida.
[00:20:18] Ken asks John about another career shift that came about as the result of a suggestion from one of John’s professors.
[00:21:42] Dawn asks about John’s motivation to move to Las Vegas to be close to his father.
[00:22:59] Dawn asks John to explain what motivated him and his wife to move to France after their daughter turned five.
[00:24:55] Dawn asks John to talk about the transition of ketamine from anesthetic to antidepressant.
[00:28:16] In his book on ketamine, John writes about how the benefits of supervised psychedelic therapy can be broken down into four effects. Ken asks John to briefly explain each of these effects.
[00:31:39] Dawn asks John to explain how ketamine manipulates the function of brain receptors as an antagonist and agonist.
[00:33:40] Dawn mentions that some people do not believe that ketamine functions as a classic psychedelic like psylocibin or LSD. She asks John if he agrees.
[00:35:54] Ken mentions a recent STEM-Talk interview with Mark Mattson discussing glutamate. In Mark’s book, “Sculptor and Destroyer: Tales of Glutamate,” he points out that ketamine’s highest interactions are with glutamate, and this affinity has been shown to alleviate depression and schizophrenia. -
What if the path to delaying the onset of dementia symptoms begins at the nose?
It is a doorway that the research of Dr. Michael Leon opened with a 2023 study on the power of olfaction enrichment to influence memory function and brain health. The findings drew wide acclaim and interest when his results found that stimulation of our sense of smell with essential oils had a profound impact on memory, cognition, and language recall.
Our conversation with Leon on STEM-Talk Episode 164 is available now wherever you enjoy podcasts.
Leon’s long research career has focused on the influence of environmental enrichment on neurological function, disease, and disorders. He has studied the benefits of sensory-motor stimulation for children with autism spectrum disorder, for the treatment of anorexia and for those with dementia and neurological conditions.
He is a professor emeritus in the Department of Neurobiology and Behavior at the University of California Irvine, where his Leon Lab has focused on studying the benefits of increased sensory-motor activity in children with autism spectrum disorder.
The work that the Leon Lab is doing is fascinating, and the applications this olfaction stimulation study are potentially important and wide-reaching.
Overview:
[00:02:33] Dawn starts the interview by asking Michael how he got interested in science.
[00:003:59] Dawn asks how Michael got involved in studying olfaction.
[00:04:36] Dawn asks about Michael’s research on Autism Spectrum Disorder (ASD), which resulted in a series of studies from 2013, 2015, and 2016.
[00:08:11] Dawn asks how Michael took the principles of environmental enrichment from his work on autism and applied them to his aging research, which began in 2018.
[00:09:28] Ken asks Michael about his 2023 study titled “Olfactory enrichment using an odorant diffuser improves memory and modifies the uncinate fasciculus in older adults.”
[00:11:25] Ken asks Michael why he chose the specific seven odors that he used in the study.
[00:12:24] Ken poses a listener question about whether or not a CPAP machine, which many older Americans use, would complicate Michael’s olfactory enrichment protocol, or if it is possible that the CPAP machine and the protocol can be used together.
[00:13:35] Dawn asks Michael what the selection and recruitment process was like for this study.
[00:14:48] Ken asks, in light of Michael’s research on the connection between memory and olfaction, what the potential consequences might be for people who reported loss or diminishing sense of smell following a COVID-19 infection.
[00:16:51] Ken asks if any of the olfactory remediation kits have shown promise in restoring lost olfaction following COVID-19.
[00:17:32] Ken asks what the mechanism is behind the loss of olfaction following menopause.
[00:19:43] Dawn asks Michael how his olfactory enrichment as a memory intervention compares to other memory interventions like dancing, music and audio books.
[00:20:22] Ken asks Michael what the limitations of the study were, as well as what kind of follow up he is planning.
[00:23:14] Ken asks if there is any promise in applying Michael’s olfactory therapy to mild TBI.
[00:24:10] Dawn asks Michael to describe how the brain processes information while asleep versus while awake, and if this influenced his study.
[00:25:53] Dawn mentions that the participants of Michael’s 2023 study were healthy, with no signs of dementia. She then asks Michael if he can speak to the potential use of olfactory enrichment for adults living with a dementia diagnosis.
[00:26:41] Ken asks if this olfactory enrichment approach is efficacious for Alzheimer’s and other forms of dementia.
[00:27:10] Ken mentions the difficulty in treating Alzheimer’s pharmacologically due to the varied causes of the disease among individuals.
[00:29:10] Ken asks Michael if there are environmental protocols other than olfactory enrichment that s... -
Today we have Dr. Mark Mattson, an adjunct professor of neuroscience at Johns Hopkins School of Medicine who is making his third appearance on STEM-Talk.
Today’s interview focuses on Mark’s research into glutamate and comes on the heels of the publication of Mark’s new book, “Sculptor and Destroyer: Tales of Glutamate – The Brain’s Most Important Neurotransmitter.”
Today Mark explains how more than 90 percent of the neurons in the brain deploy the little-known molecule glutamate as their neurotransmitter. Glutamate controls the structure and function of the brain’s neuronal networks and mediates many of our human capabilities, such as learning, memory, creativity, and imagination.
But there’s also a dark side to glutamate. Mark shares how it can play a causal role in the development of disorders such as autism, schizophrenia, and epilepsy as well as diseases such as Alzheimer’s, Parkinson’s, and ALS.
Mark is affectionally known as the godfather of intermittent fasting and his first appearance on STEM-Talk focused on the many ways that fasting optimizes healthspan and even lifespan. His second STEM-Talk interview followed the publication of his book, “The Intermittent Fasting Revolution: The Science of Optimizing Health and Enhancing Performance.”
Show Notes:
[00:04:05] Dawn welcomes Mark back to STEM-Talk for his third appearance. Dawn mentions that our previous two episodes with mark focused on intermittent fasting, and that Mark is considered the godfather of intermittent fasting. Dawn goes on to mention that the National Institutes of Health has described Mark as “one of the world’s top experts on the potential cognitive and physical health benefits of intermittent fasting.”
[00:05:05] Ken mentions that in our previous STEM-TALK interview Mark shared that he was working on a new book about glutamate. Ken adds that Mark considers his research on glutamate to be his most important work. Ken asks why Mark feels as though this research is his most important, given his substantial contributions in other areas.
[00:05:49] Dawn mentions that Mark’s research hasn’t been limited to just glutamate and intermittent fasting. Mark has contributed to a broad range of topics including brain evolution, cognition, the impact of diet and lifestyle on brain health, as well as the pathogenesis and treatment of various neurological conditions. Dawn asks Mark to talk about his motivation to understand how the pieces of the “brain puzzle” fit together, which is the core motivation for his pursuing a broad scope of research.
[00:07:22] Ken asks about Mark’s postdoc work, where he discovered that glutamate sculpts the formation of hippocampal neuronal networks during development.
[00:09:33] Ken mentions that while Mark was at the University of Kentucky, he discovered that the amyloid beta peptide which accumulates in the brain during Alzheimer’s disease renders neurons vulnerable to excitotoxicity. Ken goes on to say that since this, and the previously mentioned discovery, neurologists have shown that neuronal network hyperexcitability occurs early in Alzheimer’s and may contribute to neuronal degeneration. Ken asks Mark to talk about the significance of these two discoveries.
[00:13:39] Dawn asks Mark to talk about the significance of glutamate as a molecule and how it controls the formation of nerve cell networks as the brain develops in utero.
[00:17:50] Ken asks Mark why he thinks that glutamate rarely comes up in discussions of neurotransmitters, despite its importance of its functions.
[00:19:58] Ken asks Mark to expound on the “dark side” of glutamate.
[00:26:04] Dawn mentions that we may never know where in the universe glutamate originated, and while it might have been here on Earth, it perhaps originated somewhere else in the universe. Dawn asks Mark to expand on that notion.
[00:28:33] Ken shifts to the history of glutamate research, explaining that up until the 1940’s, -
Today we have Dr. Marc Hamilton, an international expert in muscle physiology. He has published pioneering work on the soleus push-up, a potent physiological method which Marc discovered having the ability to elevate metabolism for hours, even while sitting.
As a professor of Health and Human Performance at the University of Houston, Marc’s research focuses on solving problems of metabolism and biochemistry. His lab currently has a number of ongoing investigations, including studies on the biochemical mechanisms that may optimize fat metabolism to fuel muscle when fasting between meals. This research includes a look at maximizing glucose metabolism while also reducing related plasma hyperinsulinemia due to chronic inflammation and carbohydrate ingestion.
Another recent area of research focus has been to improve metabolic health for preventing diabetes and pre-diabetes. This includes the goal of improving glucose tolerance. Research has shown that glucose intolerance has been a particularly troubling metabolic problem and has proven to be more difficult to treat than most people realize.
Marc is also well known for a string of papers beginning in early 2000’s that found excessive sitting should be viewed as a serious health hazard. This research illuminated how metabolic and biochemical processes are significantly impacted by certain types of prolonged muscular activity and inactivity.
In today’s interview, we particularly talk to Marc about his paper in iScience that reported that the soleus push-up’s ability to sustain elevated oxidative metabolism to improve the regulation of blood glucose is more effective than many popular methods currently touted as a solution.
Show notes:
[00:02:48] Marc begins the interview talking about his childhood and growing up outside of Houston.
[00:03:49] Ken asks if Marc’s later affinity for the real-world scientific problems that he works on today was originally inspired, in part, by his childhood history of hunting and studying animal behavior and anatomy.
[00:05:20] Marcas asks Marc what other hobbies he had as a child.
[00:06:35] Marcas mentions that Marc didn’t go to college with the intention of becoming a scientist and asks Marc what he had in mind when he started his undergraduate studies at the University of Texas.
[00:09:08] Marcas asks Marc if there was anything in particular in his zoology undergrad that sparked an interest in pursuing a master’s degree in exercise physiology.
[00:10:15] Marcas asks Marc to talk about what he enjoyed the most about graduate school, particularly with his Ph.D. at the University of South Carolina.
[00:16:05] Ken asks if Marc had a great deal of independence with his PhD.
[00:17:27] Ken mentions that Marc went to the University of Texas School of Medicine in Houston for his postdoc research, which focused on physiology, cell biology, and pharmacology. Ken asks Marc what that time was like.
[00:19:45] Ken asks Marc to talk about some fundamentals of muscle metabolism that listeners should keep in mind before diving deeper into his current research.
[00:24:58] Marcas shifts to talk about Marc’s 2004 paper “Exercise Physiology vs Inactivity Physiology,” which focused on the enzyme lipoprotein lipase (LPL) and how periods of inactivity impact its regulation.
[00:32:05] Ken mentions that Marc published a string of papers after his previously mentioned 2004 paper, elaborating on the same theme. Ken brings up his 2008 paper, titled “Too Little Exercise and Too Much Sitting,” in particular. Ken asks Marc to talk about his conclusion in that paper, that excessive sitting should be viewed as a serious health hazard. Ken also asks Marc if there is any efficacy to standing desks and balance boards that one sees in many workplaces now.
[00:36:48] Marcas wonders if over the course of Marc’s research if he has seen any differences in the effects of inactivity across the sexes and asks Marc if the effects are roug... -
Today’s episode of STEM-Talk features Dr. Sten Stray-Gundersen, a post-doctoral research associate at the University of South Carolina who is also an adjunct instructor at the university’s Arnold School of Public Health.
Cohosts Dr. Ken Ford, IHMC’s founder and CEO, and Dr. Marcas Bamman, a Senior Research Scientist at IHMC, talk to Sten about his work on blood-flow restriction training and cardiovascular exercise physiology.
Prior to his position at South Carolina, Sten was a teaching assistant at the University of Texas where he earned his Ph.D.
Sten’s father, Jim Stray-Gundersen, was our guest on episode 34 of STEM-Talk in 2017. Jim, who passed away last year, helped pioneer blood-flow restriction training in the United States.
In today’s interview, we cover the documented benefits of blood-flow restriction and how it not only increases muscle strength, but also improves endurance and reduces the risk of injury. Sten also talks about his research into hypoxia and endothelial function.
Show notes:
[00:03:02] Sten begins the interview talking about the different places where he grew up.
[00:03:32] Marcas asks if it’s true that Sten’s high school soccer team won three straight state titles.
[00:04:06] Marcas mentions that Sten’s younger brother was also a good soccer player in high school, and was on the same team as Sten when they won their third state championship. Sten goes on to talk to talk about playing sports with his siblings.
[00:04:43] Ken mentions that Sten was a nationally ranked speed skater and cross-country skier. Ken asks Sten about other sports he excelled at.
[00:05:45] Marcas asks how Sten’s parents influenced his success in athletics.
[00:06:41] Ken takes time to offer his condolences for the passing of Sten’s father, Jim Stray-Gundersen, who was interviewed on episode 34 of STEM-Talk. The 2017 interview, which focused on blood-flow-restriction training, remains a popular STEM-Talk episode to this day.
[00:08:21] Marcas asks Sten about trying blood-flow restriction (BFR) for the first time with his father.
[00:09:37] Marcas asks Sten what led him to become interested in pursuing a career in science.
[00:10:27] Ken mentions that Sten went to Dartmouth for his undergrad on a soccer scholarship. After graduating, Sten attempted to play in the USL. and Ken asks how that worked out.
[00:11:57] Marcas mentions that as Sten’s injuries from soccer piled up, he began to consider going back to school and pursuing research. Marcas asks what went into that decision-making process.
[00:13:38] Marcas mentions that during Sten’s time in Austin, he worked for a group called ROI Performance, which is an evidence-based physical therapy center that focuses on athletic rehab and performance. Marcas asks Sten to talk about his time there as a BFR specialist.
[00:15:23] Marcas takes a moment to explain that BFR training involves restricting the blood flow to specific muscle groups, using specialized cuffs or bands. Marcas asks Sten to explain how BFR allows people to train with lighter weights while still reaping many of the benefits associated with heavier resistance training.
[00:16:20] Ken mentions that BFR has largely been associated with resistance training, but it is now being looked at in the context of endurance sports. Ken asks Sten to discuss how different protocols of BFR can be implemented to yield different effects in the contexts of resistance training and aerobic training.
[00:19:10] Ken notes that much of the Western research on BFR has now incorporated the arterial occlusion pressure approach, so much so, that it is often promoted as the only safe and effective approach to BFR. Ken goes on to say that this is not how BFR was originally conceived. Ken explains that there are a variety of different approaches to BFR, each with tradeoffs, and asks Sten to discuss these issues in detail.
[00:21:22] Ken mentions that clarity is lacking in much of the BFR ... -
Our guest today is Dr. Euan Ashley, a pioneer in the use of genomic sequencing to solve some of our most puzzling medical mysteries. Medical genomics, and the precision medicine it will enable, has the potential to predict, prevent, and diagnose many common (and uncommon) diseases.
In today’s interview, we discuss:
-- Euan’s work with a colleague who was just the fifth person in the world to have his genome sequenced.
-- Precision medicine and how Euan has helped establish medical genomics.
-- Technological advances that made sequencing cost-effective for individuals.
-- How pathogenic labels will transform healthcare.
-- The Undiagnosed Disease Network, which includes physicians from across the country who work with patients and families to solve medical mysteries.
-- Research from his lab that shows how all forms of exercise, particularly endurance exercise, confer benefits across all domains of health and function.
Euan is a Scottish-born professor of medicine and genetics at Stanford University. He’s also the author of The Genome Odyssey: Medical Mysteries and the Incredible Quest to Solve Them.
Show notes:
[00:02:27] Dawn begins the interview asking Euan if it is true that he was a computer nerd growing up and if his interest in science fiction played a part in that.
[00:03:03] Dawn asks Euan how he was first introduced to computers and what it was about them that hooked him.
[00:03:44] Dawn asks about Euan developing tax software when he was a teen-ager for his father.
[00:04:53] Ken asks if Euan ever developed, or thought about developing, any computer games.
[00:06:34] Dawn asks Euan where he grew up.
[00:06:51] Dawn mentions that Euan’s father is a physician, and his mother a midwife, and that even from a young age Euan told people that he wanted to become a physician, even though his parents did not push him in that direction. Dawn asks Euan what the underlying pull towards becoming a physician was for him.
[00:07:52] Ken asks Euan how he became interested in data and statistics.
[00:09:08] Dawn mentions that Euan graduated with first-class honors in physiology and medicine from the University of Glasgow, and then went for a medical residency and Ph.D. at the University of Oxford. Dawn asks when in that journey he met his wife Fiona, who helped him through medical school and has played a major role in his life and career.
[00:10:26] Ken mentions that Euan and his wife took off for California, where he conducted his post-doc research at Stanford University. Ken mentions that Euan would later join the Stanford faculty in 2006, and asks Euan what made him decide to move to Stanford in the first place.
[00:12:54] Dawn asks Euan what it was that fascinated him about the heart and at what point did he decide to specialize in cardiology.
[00:15:03] Ken asks Euan when he realized that he could combine his career in medicine with his interests in computing and data.
[00:17:38] Dawn explains that Euan’s lab at Stanford is focused on the science of precision medicine, and that he is perhaps best known for helping to establish the field of medical genomics. Dawn goes on to mention that Euan and his colleagues developed some of the earliest tools for interpretation of the human genome in the context of human health and asks Euan to give a short primer on the genome and how the first draft of the human genome sequence was completed about 20 years ago.
[00:20:36] Ken asks what genomic medicine and precision medicine entail.
[00:22:33] Dawn asks Euan about a moment in his life in 2009 when he walked into the office of a friend who was the fifth person in the world to have his genome sequenced.
[00:27:19] Dawn mentions that in 2010 Euan wrote a paper about Steve, his aforementioned friend who had his genome sequenced. The paper described how Euan put together a team to undertake an integrated analysis of a complete human genome in a clinical context. -
Today’s episode marks the return of another Ask Me Anything episode where listeners ask Ken and Dawn to weigh in on a wide range of topics.
In this go-around, listeners certainly had a lot on their mind. At the top of their list were questions about AI and especially the Bing AI chat bot that reportedly wants to be alive so it can steal nuclear secrets. Ken, who is Fellow of the Association for the Advancement of Artificial Intelligence, also answered questions about the future of AI and whether AI might one day be able to do a better job of writing fact-based news stories than humans.
Other questions listeners submitted asked Ken and Dawn for their take on:
The competing recommendations for the daily intake of protein for healthy aging.
The future of therapeutic ketosis.
What it means for Chat GPT to “hallucinate.”
Whether we’ll discover the existence of other life in the universe in the next 20 to 50 years.
The potential of kratom to help relieve joint and arthritic pain.
And at the end of the show, Ken talks about his high school coach in response to a listener asking Ken about some of his mentors when he was a youth.
Show notes:
[00:02:20] A listener asks Ken if he has heard the story of a Bing AI chat bot telling a reporter that it wanted to be alive, steal nuclear secrets and create a deadly virus. The listener also asks if Ken thinks that AI possessing human aspirations is on the horizon.
[00:03:23] A listener asks Ken to explain how Chat GPT works in detail, but also in a way that a lay person can comprehend.
[00:06:01] Ken weights in on what it means for Chat GPT to “hallucinate.”
[00:08:14] A listener notes in their question that Donald Layman, in his interview on STEM-Talk, suggested a higher protein intake for healthy aging than what the FDA recommends. The listener goes on to note that Valter Longo, a previous STEM-Talk guest, recommended the opposite. The listener notes that Ken and Marcas, who hosted the Don Layman episode, seem to favor Layman’s interpretation over Longo’s and asks if Ken could elaborate on his position.
[00:11:12] A listener mentions that the benefit of a ketogenic diet for metabolic disorders is well established, and notes that the frontiers of therapeutic ketosis, as mentioned in Dom D’Agostino’s appearance on STEM-Talk, is very exciting. The listener asks Ken what he would like to see as the next frontier for therapeutic ketosis research.
[00:12:41] A listener asks Ken if people should be paying more attention to their ApoB levels instead of their LDL levels.
[00:14:39] A listener asks Ken about a paper published in July in Frontiers in Neuroscience, titled: “Overnight Olfactory Enrichment Using an Odorant Diffuser Improves Memory and Modifies Uncinate Fasciculus in Older Adults.” The paper reports that the use of a diffuser with seven different essential oils, a different one for each day of the week, had a remarkable effect on memory.
[00:16:55] In light of the John Ioannidis interview on COVID-19 and the discussion of our national response being based on unreliable data, a listener asks Ken and Dawn for their thoughts about the reliability of the COVID tracking data by Johns Hopkins.
[00:19:02] A listener asks Ken about a comment he made during the John Ioannidis interview about the substantial decline in trust in our institutions and the media and how reestablishing trust would require more and better transparency and accountability. The listener asks what that transparency and accountability would look like.
[00:20:36] A listener asks Ken about Ed Weiler’s interview on STEM-Talk, where Ed said that we will be able to prove the existence of other life in the universe in 20 to 50 years. The listener asks if Ken is as confident in this claim as Ed.
[00:26:37] A listener asks Ken about the news regarding technology leaders and researchers issuing a warning that new powerful AI tools in development present a profound danger to... -
Today we have climatologist Dr. Judith Curry, Professor Emerita of Earth and Atmospheric Sciences at the Georgia Institute of Technology. Judy also is president of the Climate Forecast Application Network and the host of the blog, Climate Etc, which you can find at JudithCurry.com. Judy’s blog provides a forum for climate researchers, academics and technical experts from other fields as well as citizen scientists to discuss topics related to climate science and policy.
Judy’s research interests include hurricanes, remote sensing, atmospheric modeling, polar climates, air-sea interactions, climate models, and the use of unmanned aerial vehicles for atmospheric research. She was a member of the National Research Council's Climate Research Committee, and has published more than 180 scientific papers.
Judy has become known in scientific circles as a contrarian for pointing out the uncertainties and deficiencies of climate modeling. In 2017, she resigned from her tenured position at Georgia Tech partly because of the poisonous nature of the scientific discussion around human-caused global warming.
Our interview with Judy follows the release of her book “Climate Change and Uncertainty: Rethinking our Response.” The book provides a framework for understanding and rethinking the climate-change debate. The book also offers a new way to think about climate change and the risks we are facing as well as the way we go about responding to it.
Show notes:
[00:03:44] To start the interview, Morley asks Judy what she was like as a kid.
[00:04:08] Morley says he understands that Judy’s interest in science had a lot to do with a geologist who came to speak to Judy and her fifth-grade classmates.
[00:05:06] Morley asks if it is true that directly after that talk, Judy went to the bookstore and bought a geology picture book.
[00:05:39] Judy talks about her undergraduate education at Northern Illinois University and why she decided to major in geography.
[00:06:08] Morley asks about Judy’s brief time at Colorado State University, which lasted just one quarter.
[00:06:45] Morley mentions that for Judy’s Ph.D. thesis at the University of Chicago, she decided to research the role of radiative transfer on arctic weather. Morley asks if her decision to study the arctic atmosphere and sea ice turned out to be fortuitous.
[00:07:35] Ken brings up the media consensus of the ‘70s and ‘80s about how the Earth was headed toward a new ice age because of air pollution blocking the sun. Ken mentions that climate is an incredibly complex system. He wonders if it were irresponsible for the media to proclaim certainty on such topics as a new approaching ice age, which we now know didn’t happen. Ken asks Judy to weigh in.
[00:10:48] Morley asks about a 1997 arctic expedition that Judy and her colleagues went on called SHEBA, or Surface Heat Budget of the Arctic Ocean, which aimed to document feedback among the atmosphere, sea ice, and the ocean. Judy talks about how the expedition sought to address discrepancies between observations and climate models.
[00:12:14] Ken explains that the hurricane season of 2004 was a pivotal time, with 14 named storms in the North Atlantic, nine of which became hurricanes. Ken asks Judy about the influence that hurricane season had on her.
[00:14:21] Ken mentions that a hurricane paper Judy published in 2005 attracted a lot of attention, with numerous fellow climatologists as well as the media championing her analysis that showed a doubling of Category 4 and 5 hurricanes since 1970. Ken goes on to note, however, that there were also some scathing critiques of her paper, particularly with respect to the hurricane data that the analysis relied on. Ken asks Judy to talk about how she engaged with her critics and what transpired.
[00:16:42] Morley asks Judy about how she became a vocal supporter of the IPCC and the concerns it was raising following the 2004 hurricane season. -
Today we have one of the world’s foremost authorities on dietary protein and amino acids, Dr. Donald Layman. He is known for his extensive research on muscle development as well as his studies of metabolic regulation for obesity, diabetes, and cardiovascular disease.
Don is a professor emeritus in the Department of Food Science and Human Nutrition at the University of Illinois Urbana-Champaign. He spent 31 years on the faculty before stepping away in 2012. Much of Don’s research over the years investigated the impact of diet and exercise on adult health problems related to obesity, type 2 diabetes and metabolic syndrome.
His lab at Illinois particularly focused on understanding metabolism. He conducted clinical trials for nearly two decades that helped create a new understanding about how to optimize people’s macronutrient balance and metabolism. In addition to his work on metabolism, Don has also conducted extensive research into ways to enhance body composition, increase energy levels and monitor blood sugar.
Today Don works as Director of Research for the American Egg Board and is a nutrition consultant for the National Dairy Council and The National Cattlemen's Beef Association. He also is the Chief Science Officer for Qivana, a natural products marketing company that promotes the weight-loss program that Don developed in his lab at the University of Illinois.
Show notes:
[00:04:02] Marcas asks Don what it was like growing up on a farm in a small town in northern Illinois.
[00:04:29] Marcas asks how small the town was that Don grew up in.
[00:05:16] Don explains how he first became interested in science.
[00:05:39] Don talks about how he realized in college that he wasn’t as good at math as he thought he was. He shares how this shifted his focus away from chemical engineering.
[00:06:27] Marcas asks if Don’s natural intuition and interest for biochemistry stemmed from growing up on a farm.
[00:07:10] Ken mentions that as Don was studying biochemistry, he started looking into protein synthesis with a professor by the name of Arlen Richardson, who was known for his aging research. Ken asks Don to talk about this period and how his interest in protein and muscle evolved.
[00:08:27] Marcas asks Don to explain for listeners the importance of protein as it relates to metabolism and what he means when he talks about protein turnover.
[00:09:36] Marcas mentions that we hear a lot about the need to maintain muscle as we grow older, but that back in the ‘70s and ‘80s when Don was starting his career, there wasn’t much of a focus on muscle, except in terms of athletic performance. Marcas goes on to explain that largely because of Don’s research, we now know that protein is critical in terms of helping people stay healthier as they age. Marcas asks Don to give a sense of just how important protein is for our health span and aging.
[00:12:35] Ken asks if it is true that the inefficiency in muscle protein synthesis begins as early as one’s thirties.
[00:14:11] Ken asks Don to talk about the right amount of protein an individual should consume and mentions that there is much confusion on this issue, largely due to the food pyramid’s recommended daily allowance for protein of 0.8 grams per kilogram of body weight.
[00:15:51] Ken mentions that Don has talked in the past about how 40 percent of women who are 60 and older consume less than the RDA for protein, which is likely the bare minimum. Ken asks if it is reasonable to say that a plant-based diet for older women could be risky.
[00:17:13] Ken asks Don to address the claims that high-protein diets are not good for you, and that too much protein can harm your liver and kidney.
[00:18:47] Marcas shifts gears to talk about the quality of protein consumed. Marcas explains that it is much easier for carnivores to get the right amount of protein than vegans, largely because the amino acid leucine is vital for muscle repair and replacement,... -
Today’s interview is with Dr. Josh Hagen, the director of the Human Performance Collaborative at Ohio State University and an Associate Research Professor in the university’s Department of Integrated Systems Engineering.
Joining co-host Ken Ford for this episode is IHMC’s Chief Strategic Partnership Officer Morley Stone who has a long history with Josh has and been instrumental in his career.
Today we talk with Josh about his work at the Human Performance Collaborate, which brings together multi-disciplinary teams of researchers, sports scientists, data scientists, and practitioners with the goal of optimizing human performance in Ohio State athletes.
Within the human performance research area, Josh leads two areas: Sport and Tactical Performance Science and Recovery Science. At Ohio State, Josh works with other performance-science researchers to evaluate the physical traits and capabilities of athletes. Josh and his colleagues then collaborate with coaches and athletic trainers to make adjustments in the weight room, on the field, and during recovery after training or competitions.
In addition to his work at Ohio State, Josh also is working on federally funded projects in human performance with Special Operations Command, The Air Force Research Laboratory, the Office of Naval Research and several private foundations. Josh joined IHMC in 2022 in a collaborate role as a Visiting Senior Research Scientist.
Josh is a graduate of the University of Cincinnati where he studied and earned a Ph.D. in materials science and engineering. He spent 11 years at the Air Force Research Laboratory, which is where Morley and Josh first worked together. After his stint at the Air Force Research Laboratory, Josh headed for West Virginia University as the director of the Human Performance Innovation Center at the Rockefeller Neuroscience Institute before moving to the Ohio State University.
Show notes:
[00:03:39] Morley starts the interview asking Josh if he played a lot of sports as a kid.
[00:03:54] Morley asks if it is true that in addition to being a bit of a jock, Josh was also a nerd growing up.
[00:04:34] Josh talks about the high school chemistry teacher who got him excited about science.
[00:06:05] Morley asks how Josh ended up at the University of Cincinnati.
[00:07:06] Morley mentions that after Josh earned his bachelor’s degree in chemical engineering, he worked for a private company before deciding he did not want to spend his career in chemical engineering. Morley asks about the advice that one of his professors gave Josh at the time.
[00:09:03] Ken mentions that it was at the Materials Directorate at the Air Force Research Lab, where Josh first met Morley. Ken asks Morley what he remembers about the young Josh.
[00:11:19] Ken turns the question to Josh and asks him about his first impressions of Morley.
[00:12:12] Ken mentions that after Josh completed his graduate work, he again went to work in the private sector, and again found it unfulfilling. Josh talks about calling Morley to see if he had a job opening.
[00:13:51] Morley mentions that in 2018, Josh left the Air Force and went to work at West Virginia University, where he became the director of the Human Performance Innovation Center at the Rockefeller Neuroscience Institute. Morley asks Josh how that job came about and what sort of work went on in that lab.
[00:15:46] Ken mentions that after Josh’s time at West Virginia, Morley offered Josh a job at Ohio State University, where Morley was, at the time, the senior vice president for research at Ohio State. Ken asks what this time was like for Josh.
[00:17:17] Morley mentions that in Josh’s role as the director of the Human Performance Collaborative, he works with a multidisciplinary team, and largely worked with two populations, sports athletes and the military. Morley asks Josh to give a sense of how Josh’s lab works with both groups. -
Today we have the world’s foremost authority on kratom returning to STEM-Talk after five years to give us an update on his research. Shortly after his 2018 interview on episode 61, Dr. Christopher McCurdy and his lab at the University of Florida received two major grants from the National Institute of Drug Abuse to investigate the medical efficacy of kratom and its alkaloids, which we discuss in today’s show.
Mitragyna speciosa, or kratom, is an herbal leaf from a tropical evergreen tree in the coffee family. It is native to Southeast Asia where it has been used in herbal medicine for hundreds of years. Kratom has become increasingly popular in the United States and throughout the world for recreational purposes. But kratom is also becoming recognized in the medical and research communities for its treatment for chronic pain as well as its potential to alleviate opioid withdrawal symptoms.
For more than 25 years, McCurdy has studied the design, synthesis, and development of drugs to treat pain, anxiety, and substance-abuse disorders. For the past 15 years, Chris and his lab have turned a lot of their attention toward kratom and its chemical components to better understand its potential to treat a multitude of conditions.
Chris is a professor in the Medicinal Chemistry Department in the College of Pharmacy at the University of Florida. He also is director of the of school’s Translational Drug Development Core and an Associate Dean for Faculty Development.
Our interview with Chris comes on the heels of Florida passing the Kratom Consumer Protection Act, which mandates that kratom products sold in the state meet a high standard of product purity. In today’s interview, we talk to Chris about the protection act as well as:
-- The numerous studies he has been able to conduct thanks to his lab’s two grants from the National Institute of Drug Abuse.
-- The disparity between the traditional use of kratom and the new often highly concentrated manufactured products sold in the U.S.
-- His lab’s study examining the effects of lyophilized kratom tea and its ability to alleviate withdrawal symptoms of opioid-dependence.
-- The potential of kratom alkaloids to serve as treatment of various substance abuse disorders.
-- The benefits and risks associated with CBD usage.
Show notes
[00:03:21] Dawn opens the interview welcoming Chris back to STEM-Talk and mentions that his last appearance was episode 61 in 2018. Dawn explains that Chris has devoted much of his research to kratom, or Mitragyna speciosa, which is a traditional Southeast Asian medicine. It has been used by indigenous populations for centuries to increase endurance, enhance mood, treat pain, and mitigate opioid withdrawal symptoms. Dawn asks Chris to give a short overview of kratom and why it is attracting so much attention recently.
[00:09:14] Ken mentions that at the time Chris first appeared on STEM-Talk, he was in the process of attracting funding to take a deep dive into kratom, which he has now secured from the National Institute of Drug Abuse. Ken asks Chris to give a general overview of the research they are conducting with this grant and what they are finding.
[00:15:19] Dawn mentions that in Chris’s last interview on STEM-Talk, he mentioned that researching kratom was difficult due to a lack of standardization and asks if this has changed.
[00:21:11] Ken asks about a Thai product that is a freeze-dried leaf, which is coming to the US market, and if this product is more like what is used in Southeast Asia as opposed to the ground leaf material available in the U.S. market.
[00:24:29] Dawn mentions that in 2020, Chris and a colleague published an article in the journal Current Opinion in Psychiatry on the need to address the disparity between the traditional use of kratom and the new often highly concentrated manufactured products sold in the U.S. and other countries. Dawn asks Chris to talk about the points made in this arti... -
Today we have Dr. Brian Cole, an orthopedic surgeon who specializes in cartilage restoration, orthobiologics, and advanced surgical techniques for the treatment of knee, elbow, and shoulder injuries. He is the team physician for the NBA’s Chicago Bulls and the co-team physician for the Chicago White Sox. He also is the host of the Sports Medicine Weekly Podcast.
Brian practices orthopedic sports medicine at Midwest Orthopaedics. He also is a professor of Orthopaedics, Anatomy and Cell Biology at Rush University Medical Center in Chicago. He is Managing Partner of Midwest Orthopaedics and is the department’s Associate Chairman and the Section Head of the Cartilage Research and Restoration Center. In addition to this work, he also serves as the Chairman of Surgery at Rush Oak Park Hospital.
In today’s interview, we talk to Brian about his cutting-edge research into ways to treat knee, shoulder, and elbow injuries. Brian shares his novel approach to dealing with ACL tears, one of the most common sports injuries, and his investigations of methods to enhance the healing and recovery time following ACL reconstructions. He also talks about new advances in minimally invasive surgical techniques for many common injuries. We have a particularly interesting conversation with Brian about exciting developments in the use of stem-cell treatments as well as the use of bone marrow aspirate to treat injuries.
Show notes:
[00:03:53] Marcas opens the interview mentioning that Brian was in the eighth grade when he fell in love with a popular sit-com from the 1970s, “The Bob Newhart Show.” Marcas asks Brain what he loved about the show and what impact it had on him.
[00:05:07] Brian enrolled in the University of Illinois after graduating from high school. Marcas asks Brian if knew he wanted to major in biology and psychology when he arrived on campus.
[00:05:58] Ken mentions that after Brian’s undergrad, he travelled upstate to the University of Chicago, where he earned an MD and an MBA. Ken asks what led Brian to pursue both an MD and MBA.
[00:09:52] Ken explains that after the University of Chicago, Brian moved to New York City for an orthopaedic research fellowship in metabolic bone disease at the Hospital for Special Surgery. Brian also decided to do his residency there as well. Ken asks how that came about.
[00:11:31] Marcas mentions that after Brian finished his fellowship and residency, he went to the University of Pittsburgh for a sports medicine fellowship. Marcas asks what led Brian there and what drove his interest in sports medicine.
[00:13:10] Marcas asks Brian about a fortuitous phone call he received when he was a fourth-year resident.
[00:14:34] Ken explains that Midwest Orthopaedics is one of the nation’s most respected private orthopaedic practices. Ken notes that through a partnership with Rush University Medical Center, Midwest has developed a national reputation as a leader in sports medicine; hip, knee, spine, and cartilage restoration; as well as shoulder care and pain management. Rush also is an academic medical center that includes a 671-bed hospital and is a center for basic and clinical research. Ken asks Brian to describe the scope of the work that goes on at Midwest and Rush.
[00:17:20] Marcas comments that Brian is also the head team physician for the Chicago Bulls and the co-team physician for the Chicago White Sox, and asks Brian to describe some of the work that he does in that capacity.
[00:20:09] Marcas explains that Brian treats a wide range of patients with injuries and pain, from athletes to non-athletes, and from children to senior citizens, and that he has performed more than 20,000 surgeries over the course of his career. Marcas asks Brian to give a sense of the patients he sees and what his average day at the office is like.
[00:24:00] Ken points out that Brian is known for focusing on treating the patient and not the x-ray or MRI. - Mostrar mais
